Lifecore Biomedical, Inc. LFCR Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Lifecore Biomedical, Inc.’s reported figures.
Based on the most recent quarter.
The official record: Lifecore Biomedical, Inc.’s 10-Q, filed November 6, 2025, on SEC EDGAR. View the filing →
Ask your AI about Lifecore Biomedical, Inc.'s debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lifecore Biomedical, Inc.'s debt-to-equity?
- Lifecore Biomedical, Inc. (LFCR) reported debt-to-equity of 8.3× in Q1 2025.
- How has Lifecore Biomedical, Inc.'s debt-to-equity changed year-over-year?
- Lifecore Biomedical, Inc.'s debt-to-equity decreased by 14.9% year-over-year, from 9.8× to 8.3×.
- What is the long-term trend for Lifecore Biomedical, Inc.'s debt-to-equity?
- Over 3 years (2021 to 2025), Lifecore Biomedical, Inc.'s debt-to-equity has grown at a 106.0% compound annual growth rate (CAGR), from 1× to 8.3×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.